Targets › SLC2A1
1 program from 1 company in 1 trial: 1 Phase 3; Hematology; next expected readout Jun 2027.
Facilitative glucose transporter, which is responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses. (UniProt, P11166)
Open in Phaseline: the race on SLC2A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Anna Raciborska | fluorodeoxyglucose (18F-FDG) Glucose analog positron emission tomography imaging agent | SLC2A1 | Phase 3 | Histiocytosis | Jun 2027 |
Histiocytosis (1)
small molecule (1)
Anna Raciborska (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.